Fixed Dose Combinations Approved By DCG (I) From 1st January 2020 to 31st October 2020

1.	Each uncoated bilayered tablet contains: Glimepiride IP + Voglibose IP + Metformin HCl IP (as ER) (1mg + 0.2mg + 500mg & 2mg + 0.2mg + 500mg)	As 3 rd line treatment of type 2 diabetes mellitus when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.	
2.	Each Film coated tablet contains: Sildenafil + Dapoxetine (100mg + 60mg, 50mg + 60mg & 50mg + 30mg)	For the treatment of co-existing erectile dysfunction and premature ejaculation in men 18 to 64 years of age.	10.02.2020
3.	Each Uncoated Bilayered Tablet Contains: S(-) Amlodipine Besylate IP eq.to S(-) Amlodipine + Telmisartan IP (5mg + 40mg & 2.5mg + 40mg)	It is indicated for the treatment of essential hypertension.	14.02.2020
4.	Each film coated tablet contains: Efonidipine Hydrochloride Ethanolate20mg Telmisartan IP40mg	It is indicated for the management of stage II hypertension.	24.02.2020
5.	Each uncoated bilayered tablet contains: Gliclazide IP (as extended release form)60mg Metformin Hydrochloride IP (as extended release form)1000mg	For the treatment of noninsulin dependent diabetes (Type-II) in adult patients where single drug therapy, diet and exercise do not result in adequate glycaemic control.	03.03.2020
6.	Each film coated bilayered tablet Contains: Montelukast sodium eq. to Montelukast IP10mg Bilastine20mg	For the treatment of allergic rhinitis in adults.	09.03.2020
7.	Each film coated bilayered tablet contains: Metoprolol Succinate IP eq. to Metoprolol Tartarate IP (as Extended Release) + Telmisartan IP + Chlorthalidone IP (25mg + 40mg + 12.5mg & 50mg + 40mg + 12.5mg)	For the treatment of essential hypertension with stable coronary artery disease.	17.03.2020

8.	Sodium Alginate IP 250mg + Sodium Bicarbonate IP 133.5mg + Calcium Carbonate IP 80mg per 5ml oral liquid.	Indicated for the treatment of heartburn and indigestion.	09.04.2020
9.	Each capsule contains: Glycopyrrolate USP eq. to Glycopyrronium 12.5mcg Formoterol Fumarate Dihydrate IP 12mcg Fluticasone Propionate IP 250mcg Dry powder for inhalation	It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	16.04.2020
10.	Sodium Hyaluronate0.15% w/v Polyethylne Glycol 4000.4%w/v Propylene Glycol0.3%w/v Lubricant eye drops	For the temporary relief of burning and irritation due to dryness of the eye and for use in lubricating and rewetting of all silicone hydrogel and soft hydrophilic contact lenses.	22.04.2020
11.	Each film coated bilayered tablet contains: Azilsartan Kamedoxomil eq to Azilsartan Medoxomil + Cilnidipine (40mg + 5mg & 40mg+ 10mg)	For the treatment of stage II hypertension.	24.04.2020
12.	Each film coated tablet contains: Capecitabine IP + Cyclophosphamide IP eq. to anhydrous Cyclophosphamide (400mg + 21.4mg eq. to 20mg & 700mg + 32.1mg eq. to 30mg)	For the treatment of patients with metastatic breast cancer after failure of prior anthracycline and /or taxane chemotherapy.	28.04.2020
13.	Tropicamide IP 0.2mg + Phenylephrine Hydrochloride IP 3.1mg + Lidocaine Hydrochloride IP 10mg per ml injection. Intracameral Injection	It is indicated for cataract surgery to obtain mydriasis and intraocular anesthesia during surgical procedure.	04.05.2020
14.	Each film coated tablet contains: Alogliptin Benzoate 17mg eq. to Alogliptin + Metformin Hydrochloride (12.5mg + 500mg & 12.5mg + 1000mg)	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	18.05.2020

15.	Each ml contains Timolol Maleate EP5mg Brinzolamide10mg Eye drops suspension.	Decrease of intraocular pressure (IOP) in adult patients with open–angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	14.5.2020
16.	Per 1000ml contains (after mixing) Glucose Monohydrate EP	MultiBic Potassium-free is indicated for intravenous use as substitution solution in haemofilteration and haemodiafilteration, and as dialysis solution in haemodailysis and haemodiafiltration.	15.05.2020
17.	Per 12.5mg blister contains: Fluticasone Furoate100mcg Umeclidinium bromide 74.2mcg eq. to Umeclidinium62.5mcg Vilanterol trifenatate 40mcg eq. to Vilanterol25mcg	Indicated for maintenance treatment to prevent and relieve symptoms associate with chronic obstructive pulmonary disease (COPD).	18.05.2020
18.	MultiBic 2 mmol/l potassium Per 1000ml contains (After mixing) Potassium Chloride	MultiBic 2 mmol/l and 4 mmol/l Potassium is indicated for intravenous use as substitution solution in haemofiltartion and haemodiafiltration, and as dialysis solution in haemodialysis and haemodiafiltration.	15.05.2020
	MultiBic 4 mmol/l potassium Per 1000ml contains (After mixing) Potassium Chloride		
	Solution for Haemodialysis/Heamofiltration		

19.	Disoidum Phosphate Dihydarte EP	Biphozyl is used as replacement solution and as a dialysate for treatment of acute kidney injury during continuous renal replacement therapy. Biphozyl is used in a post –acute phase after initiation of renal replacement therapy when therapy when pH, potassium and phosphate concentration have returned to normal. Biphozyl is also used when other buffer sources are available as well as during regional citrate anticoagulation. Moreover, Biphozyl is used in patients with hypercalcaemia. Biphozyl may also be used in cases of drug poisoning or intoxications when the substances are dialysable or filterable.	21.05.2020
20.	Sodium Citrate5.2900g/L Sodium Chloride5.0300g/L Solution for Haemofiltration	Regiocit is used as replacement fluid for continuous renal replacement therapy (CRRT) using regional citrate anticoagulation. Citrate is particularly relevant when systemic anticoagulation with heparin is contraindicated for example in patients with increased bleeding risk.	
21.	Each kit contains: A) 14 Ticagrelor tablets90mg Each film coated tablet contains: Ticagrelor IP90mg B) 7 Aspirin Gastro-resistant tablets IP75mg Each enteric coated tablet contains: Aspirin IP75mg	For the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with acute coronary syndromes (ACS) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG) where both Ticagrelor and Aspirin are required.	29.05.2020
22.	Amoxicillin Trihydrate759.04 mg eq. to Amoxicillin free acid652.78 mg Potassium Clavulanate61.48 mg eq. to Clavulanic acid50.41mg per 5ml powder for reconstitution into suspension	It is indicated for short term treatment of paediatric patients with bacterial infections at the following sites when caused by amoxicillin-clavulanate-susceptible organisms: 1. Upper Respiratory Tract Infections (including ENT) e.g. • Acute otitis media (AOM), persistent AOM, or recurrent AOM, typically caused by Streptococcus pneumonia Haemophilus influenzae and Moraxella catarrhalis.	08.06.2020

		 Tonsillo-pharyngitis and sinusitis, typically caused by Streptococcuspneumonia. Haemophilus Influenza Moraxella catarrhalis and Streptococcus pyogenes. 	
		2. Lower Respiratory Tract Infections e.g. lobar and bronchopneumonia typically caused by Streptococcus pneumonia Haemophilus influenza and Moraxella catarrhalis	
		3. Skin and Soft Tissue Infections typically caused by Staphylococcus aureus and Streptococcus pyogenes.	
		4. Urinary tract infections e.g. cystitis, pyelonephritis	
		 Penicillin minimum inhibitory concentration (MIC) less than or equalto 4 micrograms/ml Some members of these species of bacteria producebeta-lactamase, rendering them insensitive to amoxicillin alone. 	
23.	Film coated bilayered tablets contains: Metformin Hydrochloride IP500mg Evogliptin Tartrate5mg (In additional Strength)	As an adjunct to diet and exercise to improve glycaemic control in adults patients with type 2 diabetes mellitus who are appropriate for co-administration of Evogliptin and Metformin. Patients with inadequate glycaemic control on Metformin monotherapy alternative for combination therapy of Evogliptin and Metformin.	26.06.2020
24.	Film coated bilayered tablet contains: Pregabalin IP (As prolonged Release)75mg	For the treatment of chronic low back pain associated with neuropathic component.	15.07.2020
	Etoricoxib IP60mg (In additional Strength)		

25.	Glycopyrronium IP25mcg Formoterol Fumarate IP12mcg Budesonide IP400mcg Inhalation Powder	Indicated as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).	17.07.2020
26.	Zinc chloride Ph. Eur	To meet basal to moderately increased requirements of trace elements in intravenous nutrition.	30.07.2020
27.	Uncoated tablets contains: Aceclofenac IP200mg (as extended release) Rabeprazole20mg (as delayed release) (In additional dosage form)	It is indicated for the treatment of Painful inflammatory conditions associated with gastroduodenal ulcers.	10.08.2020
28.	Uncoated tablets contains: Azelnidipine IP8mg/8mg Olmesartan Medoxomil IP20mg/40mg	For the treatment of patients with stage II hypertension.	14.08.2020

29.	Glycopyrrolate IP9mcg Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate4.8mcg Per actuation deliver Inhalation Aerosol (In additional Strength)	Indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.	14.08.2020
30.	Didecyl dimethyl Ammonium Chloride	Antimicrobial product for use against Novel coronavirus SARS-Cov-2, the cause of COVID-19.	14.08.2020
31.	Octyl Decyl Dimethyl Ammonium Chloride	Antimicrobial product for use against Novel Coronavirus SARS-Cov-2, the cause of COVID-19.	14.08.2020
32.	Each tablet contains: Vildagliptin50mg/50mg Metformin Hydrochloride (Sustained Release) IP500mg/1000mg	For the treatment of type_II diabetes mellitus when single drug therapy along with diet, exercise do not result in adequate glycemic control.	18.08.2020
33.	Film coated bilayered tablet contains: Azelnidipine8mg/8mg Telmisartan40mg/80mg	For treatment of Stage-II Hypertension.	19.08.2020

34.	Each vial contains:	For the treatment of bacterial infections.	19.08.2020
	Amoxycillin Sodium IP (sterile) eq. to Amoxycillin125mg		
	Potassium Clavulanate IP (sterile) eq. to Clavulanate25mg		
	Injection		
35.	Each film coated tablets contains: Efonidipine Hydrochloride Ethanolate20mg/20mg	It is indicated for the management of Stage - II Hypertension.	25.08.2020
	Metoprolol Succinate (Extended Release)25mg/50mg		
36.	Each uncoated bilayered tablets contains: Atorvastatin Calcium IP eq. to Atorvastatin10mg/20mg Clopidogrel Bisulphate IP eq. to Clopidogrel75mg/75mg (In additional dosage form)	Post coronary intervention and acute syndrome.	23.09.2020
37.	Each Dispersible tablets contains: Lamivudine USP60mg Abacavir Sulphate USP120mg	Indicated in the treatment of HIV-1 infection in children.	06.10.2020
38.	Each tablet contains: Tenofovir Alafenamide Fumarate 25mg Emtricitabine200mg (In additional Indication)	Indicated for use in high risk adults and adolescents weighing at least 35kg for PrEP to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex.	12.10.2020
39.	Each 1.8ml solution for injection contains: Lignocaine Hydrochloride Ph. Eur36mg Adrenaline Tartrate Ph. Eur0.0225mg	It is a local anaesthetic indicated for the local and loco-regional anaesthesia in dental surgery in adults and in children and adolescents aged 4 to 18 years of age.	12.10.2020

		It is appropriate for procedures of long durations and when there is a risk of significant bleeding into the operative field.	
40.	Each 1.7ml solution for injection: Articaine Hydrochloride EP68mg Adrenaline Tartrate EP0.0300mg	It is a local anaesthetic indicated for the local and loco-regional anaesthesia in dental procedures in adults. It is intended for adults, adolescents and in children over 4 years old.	14.10.2020
41.	Each Actuation delivers (Ex-actuator) contains: Glycopyrrolate IP9.0mcg Formoterol Fumarate dihydrate IP eq. to Formoterol Fumarate4.8mcg Inhalation Aerosol (In additional strength)	Indicated for the long term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.	26.10.2020

- Note 1: It may be stated that the above list of FDC s is prepared as per the records available with the office of DCG (I). In case any inconsistency is observed, same may be brought to the notice of DCG (I) for necessary action.
- Note 2: As per DCGI letter dated 23.09.2011, 04.04.2012 & 13.09.2013 regarding limiting of Paracetamol in prescription combination products, lowering of Paracetamol content to 325mg is applicable to the combinations of paracetamol with other analgesic/anti-inflammatory drugs.